article thumbnail

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

back in 2003 — so we’ve known for over 16 years that in the U.S., From 2003 to 2019, the theory that prices are the primary driver of America’s spending more on health care than any other country is still the case. Two news items illustrate this issue in real time.

BioTech 159
article thumbnail

The Funding Spree for Neuroscience Startups: Venture Capital, Angel Investors, and Big Pharma betting big on Neuroscience

Lloyd Price

Pfizer aims to invest $150 million in biotech startups focused on neurometabolic disorders, neurodegeneration, and neuroinflammation. As of June 2018, the DDF has $350 million in funds and a portfolio of 16 investments focused on early intervention and treatment for dementia.

BioTech 40
article thumbnail

Will Foot Ulcer Treatment Survive Medicare Rollback?

Insulin Nation

A 2003 study on Dermagraft undertaken throughout 35 U.S. In a recent Fierce Biotech article, CEO MacKay warned his staff of “heartbreaking” staff cuts to make the new pricing structure work. to 26.3%) as traditional wound care in closing diabetic foot ulcer wounds during a 12-week test period, for example.